VENUSREM · Health Care · 2026-08-21

Venus Remedies Ltd

5.4★ FairSolid +5.8Stage 2 · wk 21In scan: Pullback Hunter · Prop ScanMARKET: BULL RISING · 2026-08-21
₹1,738.1
-1.56% today
₹2,326 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.

Visit company website →
P/E (TTM)
21.3
Forward —
Earnings Growth (YoY)
+126.4%
Revenue +35.6%
ROE
+16.8%
Profit margin +13.1%
vs 52W High
-10.7%
₹431.3 lo₹1,947 hi
10.7% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 21
1w13w26w
Week 21 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
62.9%
200 DMA: ₹1,067.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.31x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -1.3% vs MA50 +8.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #1 of 84 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #1 of 58 Stage 2 stocks in this industry. Top stock in industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S2 15w
S2 16w
S4 27w
S2 17w
S2 14w
S2 22w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 8w → S2 16w → S3 13w → S4 3w → S1 3w → S2 9w → S3 4w → S4 27w → S1 6w → S2 17w → S3 7w → S2 14w → S3 3w → S2 22w current
Total tracked: 168 weeks across 15 stage runs.
1M
+5.0%
3M
+60.6%
6M
+135.7%
YTD
+120.6%
1Y
+266.7%
Scan Membership
Pullback Hunter
Latest: 2026-07-24
Prop Scan
Latest: 2026-07-24
60 appearances in last 60 days. First seen: 2026-06-01.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 21 · Vol —x
2026-08-20S2
Wk 21 · Vol —x
2026-08-19S2
Wk 21 · Vol —x
2026-08-18S2
Wk 21 · Vol —x
2026-08-17S2
Wk 20 · Vol —x
2026-08-14S2
Wk 20 · Vol —x
2026-08-13S2
Wk 20 · Vol —x
2026-08-12S2
Wk 20 · Vol —x
2026-08-11S2
Wk 20 · Vol —x
2026-08-10S2
Wk 19 · Vol —x
2026-08-07S2
Wk 19 · Vol —x
2026-08-06S2
Wk 19 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹1,717.5
200 DMA
₹1,067.1
52W High
₹1,947
52W Low
₹431.3
5D Low
₹1,738.1
Resistance levels (recent highs)
20d High
₹1,819.5
60d High
₹1,947
120d High
₹1,947
250d High
₹1,947
Next resistance
+4.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.